BlackRock’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-19,179,344
| Closed | -$1.01B | – | 5285 |
|
|
2020
Q3 | $1.01B | Sell |
19,179,344
-376,701
| -2% | -$15.6M | 0.04% | 459 |
|
|
2020
Q2 | $651M | Buy |
19,556,045
+1,338,423
| +7% | +$42.6M | 0.03% | 578 |
|
|
2020
Q1 | $496M | Buy |
18,217,622
+933,884
| +5% | +$26M | 0.02% | 610 |
|
|
2019
Q4 | $341M | Buy |
17,283,738
+1,501,351
| +10% | +$24M | 0.01% | 1099 |
|
|
2019
Q3 | $205M | Buy |
15,782,387
+175,882
| +1% | +$2.12M | 0.01% | 1389 |
|
|
2019
Q2 | $194M | Buy |
15,606,505
+438,679
| +3% | +$5.82M | 0.01% | 1458 |
|
|
2019
Q1 | $220M | Buy |
15,167,826
+1,392,685
| +10% | +$17.8M | 0.01% | 1349 |
|
|
2018
Q4 | $152M | Buy |
13,775,141
+1,694,797
| +14% | +$23.6M | 0.01% | 1518 |
|
|
2018
Q3 | $318M | Buy |
12,080,344
+399,232
| +3% | +$10.8M | 0.01% | 1126 |
|
|
2018
Q2 | $239M | Buy |
11,681,112
+925,524
| +9% | +$19.9M | 0.01% | 1329 |
|
|
2018
Q1 | $195M | Buy |
10,755,588
+282,272
| +3% | +$4.71M | 0.01% | 1382 |
|
|
2017
Q4 | $146M | Buy |
10,473,316
+82,691
| +0.8% | +$1.12M | 0.01% | 1605 |
|
|
2017
Q3 | $192M | Buy |
10,390,625
+990,140
| +11% | +$16.6M | 0.01% | 1384 |
|
|
2017
Q2 | $159M | Buy |
9,400,485
+626,415
| +7% | +$9.53M | 0.01% | 1469 |
|
|
2017
Q1 | $117M | Buy |
8,774,070
+8,760,556
| +64,826% | +$137M | 0.01% | 1669 |
|
|
2016
Q4 | $203K | Sell |
13,514
-853
| -6% | -$11.3K | ﹤0.01% | 2134 |
|
|
2016
Q3 | $168K | Buy |
14,367
+921
| +7% | +$10.8K | ﹤0.01% | 2281 |
|
|
2016
Q2 | $145K | Buy |
13,446
+9,245
| +220% | +$95.4K | ﹤0.01% | 2291 |
|
|
2016
Q1 | $39K | Buy |
4,201
+2,299
| +121% | +$24.7K | ﹤0.01% | 2505 |
|
|
2015
Q4 | $28K | Buy |
1,902
+578
| +44% | +$9.67K | ﹤0.01% | 2404 |
|
|
2015
Q3 | $22K | Sell |
1,324
-310
| -19% | -$6.35K | ﹤0.01% | 2343 |
|
|
2015
Q2 | $37K | Buy |
1,634
+265
| +19% | +$5.28K | ﹤0.01% | 2111 |
|
|
2015
Q1 | $21K | Hold |
1,369
| – | – | ﹤0.01% | 2352 |
|
|
2014
Q4 | $16K | Hold |
1,369
| – | – | ﹤0.01% | 2489 |
|
|
2014
Q3 | $15K | Hold |
1,369
| – | – | ﹤0.01% | 2511 |
|
|
2014
Q2 | $16K | Sell |
1,369
-132
| -9% | -$1.56K | ﹤0.01% | 2513 |
|
|
2014
Q1 | $17K | Sell |
1,501
-97,000
| -98% | -$1.64M | ﹤0.01% | 2453 |
|
|
2013
Q4 | $1.74M | Buy |
98,501
+97,000
| +6,462% | +$1.63M | ﹤0.01% | 1052 |
|
|
2013
Q3 | $22K | Hold |
1,501
| – | – | ﹤0.01% | 2242 |
|
|
2013
Q2 | $22K | Buy |
+1,501
| New | +$19.8K | ﹤0.01% | 2261 |
|
BlackRock's MNTA Position: Q4 2020 in Review
BlackRock sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q4 2020, closing a stake of 19,179,344 shares — an estimated $1.01B sold.
BlackRock first reported a position in MNTA in Q2 2013 and held it in 30 quarters. The position peaked at $1.01B in Q3 2020. 0 funds tracked by Wall St. Rank hold MNTA as of Q4 2020.
- BlackRock reported no remaining Momenta Pharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
- BlackRock sold 19,179,344 Momenta Pharmaceuticals, Inc. shares in Q4 2020, an estimated $1.01B.
- BlackRock first reported a position in Momenta Pharmaceuticals, Inc. in Q2 2013 and held it in 30 quarters.
- BlackRock's Momenta Pharmaceuticals, Inc. position peaked at $1.01B in Q3 2020.
- 0 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q4 2020.
Based on BlackRock's 13F filing for Q4 2020, filed 5 Feb 2021.